Research presented at TMS ties hormone therapy taken alongside semaglutide to significantly greater weight loss in midlife women with overweight or obesity.
Recap by typeshit. Full story at HealthDay on MSN.
PHL17 shares findings that people on Ozempic and similar drugs are cutting alcohol spending at bars, restaurants and home.
Omer Raheem says he presented his team's work on GLP-1 therapies past weight loss at the ISSM Journals Webinar 2026.
The rundown covers CagriSema, retatrutide, MariTide, VK2735 and Roche's enicepatide, which the company says cut weight by 15.5% on average in a mid-stage trial.
Zhavoronkov links recorded ARDD 2026 sessions, among them Lilly's Kevin Duffin speaking on tirzepatide and aging clocks.
Judge Zahid Quraishi found Novo hadn't shown harm, since Wegovy prescriptions held steady while the ads ran. Novo says the false advertising case continues.
Vomiting fell to 43% of patients on tradipitant versus 58.5% on placebo. Vanda plans to seek an expanded approval for GLP-1-induced vomiting.
Loading…